Large-scale real-life analysis of survival and usage of therapies in multiple myeloma.
Multiple myeloma
Real world data
Survival
Treatments
TriNetX
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
19 07 2023
19 07 2023
Historique:
received:
12
03
2023
accepted:
26
06
2023
medline:
21
7
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
Survival in multiple myeloma has improved significantly in recent years, especially in young patients. We reviewed the evolution of the survival of patients with MM in three groups based on age at MM diagnosis over three time periods between 1999 and 2020 at our 12 de Octubre Hospital institution (H12O). Then, to confirm our results, we used data from TriNetx, a global health research platform that includes patients from Europe to US. Finally, we analysed differences in the patterns of treatment between networks across the world. Kaplan‒Meier analysis was used to estimate survival probabilities, and between-group differences were tested using the log-rank test and hazard ratio. For patients from H12O, the median OS was 35.61, 55.59 and 68.67 months for the 1999-2009, 2010-2014 and 2015-2020 cohorts, respectively (p = 0.0001). Among all patients included in the EMEA network, the median OS was 20.32 months versus 34.75 months from 1999-2009 versus 2010-2014. The median OS from the 2010-2014 versus 2015-2020 time cohorts was 34.75 months versus 54.43 months, respectively. In relation to the US cohort, the median OS from before 2010 versus 2010-2014 was not reached in either time cohort and neither when comparing the 2010-2014 versus 2015-2019 time cohorts. Bortezomib is the most commonly used drug in the EMEA cohort, while lenalidomide is the most commonly used drug in the US cohort. This large-scale study based on real-world data confirms the previous finding that MM patients have increased their survival in the last two decades.
Identifiants
pubmed: 37468911
doi: 10.1186/s13045-023-01474-w
pii: 10.1186/s13045-023-01474-w
pmc: PMC10357768
doi:
Substances chimiques
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Myeloma in the real world: What is really happening? Clin Lymphoma Myeloma Leuk. 2017;17(3):133–44.
doi: 10.1016/j.clml.2016.12.002
pubmed: 28153487
Kaur G, Mejia Saldarriaga M, Shah N, Catamero DD, Yue L, Ashai N, et al. Multiple myeloma in hispanics: incidence, characteristics, survival, results of discovery, and validation using real-world and connect mm registry data. Clin Lymphoma Myeloma Leuk. 2021;21(4):e384–97.
doi: 10.1016/j.clml.2020.11.013
pubmed: 33339770
Pozzi S, Marcheselli L, Bari A, Liardo EV, Marcheselli R, Luminari S, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol. 2013;163(1):40–6.
doi: 10.1111/bjh.12465
pubmed: 23889344
Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401–19.
doi: 10.1016/j.clml.2018.06.018
pubmed: 30030033
Kumar S, Williamson M, Ogbu U, Surinach A, Arndorfer S, Hong W. Front-line treatment patterns in multiple myeloma: an analysis of U.S.-based electronic health records from 2011 to 2019. Cancer Med. 2021;10(17):5866–77.
doi: 10.1002/cam4.4137
pubmed: 34402201
pmcid: 8419764
Pydi VR, Bala SC, Kuruva SP, Chennamaneni R, Konatam ML, Gundeti S. Multiple myeloma in young adults: a single centre real world experience. Indian J Hematol Blood Transfus. 2021;37(4):679–83.
doi: 10.1007/s12288-021-01410-3
pubmed: 34690457
pmcid: 8523599
Nasr F, Ghoche AA, Diab S, Nasr L, Ammanouil E, Riachy C, et al. Lebanese real-world experience in treating multiple myeloma: a multicenter retrospective study. Leuk Res Rep. 2021;15:100252.
pubmed: 34141564
pmcid: 8188546
Akizuki K, Matsuoka H, Toyama T, Kamiunten A, Sekine M, Shide K, et al. Real-world data on clinical features, outcomes, and prognostic factors in multiple myeloma from Miyazaki Prefecture, Japan. J Clin Med. 2020;10(1):105.
doi: 10.3390/jcm10010105
pubmed: 33396800
pmcid: 7795356
Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Muñoz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11(12):198.
doi: 10.1038/s41408-021-00588-z
pubmed: 34893583
pmcid: 8661359
Sanz A, Ayala R, Hernández G, Lopez N, Gil-Alos D, Gil R, et al. Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network. Blood Cancer J. 2022;12(6):94.
doi: 10.1038/s41408-022-00692-8
pubmed: 35750670
pmcid: 9232604
Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, et al. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods. Leukemia. 2021;35(12):3600–3.
doi: 10.1038/s41375-021-01250-0
pubmed: 34099876
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8.
doi: 10.1038/leu.2013.313
pubmed: 24157580